Cantor Fitzgerald Reaffirms Overweight Rating for Eli Lilly and Company (NYSE:LLY)

Cantor Fitzgerald reissued their overweight rating on shares of Eli Lilly and Company (NYSE:LLY) in a research report report published on Tuesday morning, Benzinga reports. The brokerage currently has a $885.00 price objective on the stock, up from their previous price objective of $815.00.

A number of other research analysts have also weighed in on the stock. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a research note on Tuesday, February 6th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a neutral rating in a research note on Thursday, April 11th. DZ Bank downgraded Eli Lilly and Company from a buy rating to a hold rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. TheStreet raised shares of Eli Lilly and Company from a c+ rating to a b rating in a research report on Friday, March 8th. Finally, Citigroup raised their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a buy rating in a research report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $757.95.

Eli Lilly and Company Stock Down 2.8 %

Shares of LLY opened at $734.97 on Tuesday. The stock has a 50 day moving average price of $761.75 and a 200 day moving average price of $670.56. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. The stock has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.57 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.62 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post 13.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $5,992,890,000. International Assets Investment Management LLC boosted its position in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Sapient Capital LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $682,139,000. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $435,736,000. Finally, Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.